This may suggest that with the use of B7H3-targeted therapies, attention should be focused on the distribution of B7H3 within tumor cells, as high B7H3 expression within the tumor interstitium could mislead clinical evaluations prior to treatment. This evidence concerns the gene CD276 and neoplasm.